Corient Private Wealth LLC Purchases 8,922 Shares of Ralliant Corporation $RAL

Posted by George Bondi on Jul 2nd, 2026

Corient Private Wealth LLC increased its holdings in shares of Ralliant Corporation (NYSE:RAL – Free Report) by 58.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,191 shares of the company’s stock after buying an additional 8,922 shares during the period. Corient Private Wealth LLC’s holdings in Ralliant were worth $1,232,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Cetera Investment Advisers bought a new stake in shares of Ralliant in the second quarter worth $700,000. Russell Investments Group Ltd. bought a new position in Ralliant during the 2nd quarter worth $1,465,000. EverSource Wealth Advisors LLC bought a new position in Ralliant during the 2nd quarter worth $39,000. First Trust Advisors LP acquired a new position in Ralliant during the 2nd quarter worth about $2,013,000. Finally, Federated Hermes Inc. acquired a new position in Ralliant during the 2nd quarter worth about $326,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. TD Cowen raised their price objective on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 20th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Wall Street Zen cut shares of Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday. Truist Financial reissued a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Finally, Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Wednesday, May 27th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Ralliant currently has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Check Out Our Latest Stock Report on RAL

Ralliant Price Performance

Shares of NYSE RAL opened at $71.93 on Thursday. The firm has a market capitalization of $8.05 billion and a P/E ratio of -6.57. The firm’s 50-day moving average price is $59.71 and its 200-day moving average price is $51.69. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41.

Ralliant (NYSE:RAL – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $534.60 million for the quarter. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts anticipate that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is currently -1.83%.

Ralliant Profile

(Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.